文档介绍：-1396- 实验与检验医学 2021 年 12 月第 39 卷第 6 期 Experimental and Laboratory Medicine^ ,
nd its evaluation criteria were established. This system was used to make a preliminary morphological re­
port on those patients who meet the criterion. The preliminary report and the formal report of the patient were compared with the
confirmed report by the clinical coincidence score (CCS) analysis, respectively. The maximum score of CCS is 4 points, and M3
points means that both reports are consistent. Results The data from 848 patients were collected and 820 (%) met the re­
porting criterion of PMDSS. There were 679 patients (%) who completed the preliminary report, and their CCS score was 3.
53±, Among these 679 patients, the preliminary report with CCSM3 was 640 cases (%) and the formal report with CCSM
3 was 660 (%). There was no statistical difference between the preliminary report and the formal report (jR>). Conclusion
The preliminary report of marrow cytomorphology plays a key role in the early diagnosis and treatment of newly diagnosed patients
with hematological malignancies, and is an important method for laboratories to participate in clinical emergency treatment of these
patients.
Key words： marrow cytomorphology; preliminary report; hematolog